tirzepatide shortage The FDA says the Zepbound is over. That's rattling the weight loss industry Eli Lilly's tirzepatide is off

Beyond these specific applications, Retatrutide is being evaluated for its broader impact on cardiometabolic health

Retatrutide is currently in Phase 3 clinical trials with FDA approval expected in 2025-2026

Call 999 or attend your nearest A&E immediately if you experience: Signs of a severe allergic reaction (anaphylaxis): swelling of the face, lips, tongue or throat

Sources Eli Lilly TRIUMPH-4 topline results (December 2025) Eli Lilly TRIUMPH-1 Phase 3 topline results, including 80-week and 104-week extension data (May 21, 2026) Cleveland Clinic Health Library: Dysesthesia Encyclopedia of Neurological Disorders: Dysesthesia Journal of Peripheral Nervous System: Neuropathic pain mechanisms Frequently Asked Questions Dysesthesia involves abnormal touch sensations without appropriate external stimulus

Regenerative Medicine of Iowa, PC

showing robust prescription growth driven by expanding indications and direct-to-consumer pharmaceutical marketing